At a glance
| Wegovy | Contrave | |
|---|---|---|
| Form | Weekly injection | Twice-daily tablet |
| How often | Injection: once-weekly | Twice-daily oral tablet — no injection |
| Weight loss in trials | Up to 14.9% — STEP 1 (68 weeks) | Up to 9.3% — COR-BMOD (56 weeks) |
| FDA approved | 2021 | 2014 |
| Made by | Novo Nordisk | Currax Pharmaceuticals |
| How it works | A GLP-1 analogue with an extended half-life of approximately one week. | Bupropion activates appetite-suppressing nerve cells in the brain's hunger control centre (the hypothalamus). |
| Monthly cost, self-pay | ~$1,350/mo | $100–$400/mo |
| Most reported reaction | Nausea 44% (STEP 1) | Nausea 33% (COR-I) |
Every figure in this table is read from the same trial and label records used everywhere else on this site.
Weight loss in each drug's main trial
No head-to-head trial has compared these two drugs.
STEP 1 (68 weeks)
COR-BMOD (56 weeks)
In clinical trials, participants taking semaglutide lost on average up to 14.9% of their starting body weight, and participants taking naltrexone / bupropion ER lost on average up to 9.3%. Those numbers come from two different studies: STEP 1 enrolled 1,961 adults with obesity or overweight with comorbidities, no type 2 diabetes over 68 weeks against placebo, while COR-BMOD enrolled adults with obesity, with intensive behaviour therapy over 56 weeks against placebo + intensive behaviour therapy. Who took part, how long each trial ran and what each drug was measured against all move the percentage, so the two figures are not a measured difference between the drugs.
Monthly cost, self-pay
The bar spans the range in each drug's price record — lowest listed price to highest.
Injection: ~$1,350/month list price. Novo Nordisk NovoCare programme available. The Wegovy pill is priced separately (see the oral pill entry).
~$100–$400/month (brand). Generic available in some markets.
Self-pay prices are what the manufacturer or the pharmacy lists, not what most people end up paying. Wegovy: ~$1,350/month. Contrave: $100–$400/month. Insurance, dose and pharmacy all change both figures.
Side effects reported in the trials
Both trials reported 3 reactions in common. Each rate is the percentage of participants who reported it in the trial named beside it, so the two columns are not from the same study.
A rate is the share of trial participants who reported that reaction, not a prediction for any one person.
How they differ in practice
How you take it
- Wegovy — Two forms: once-weekly injection (2.4 mg) OR once-daily pill (25 mg). Same drug, similar results, very different cost and convenience.
- Contrave — Oral extended-release tablet, twice daily
Dose build-up
- Contrave — titrated to 32/360 mg/day over 4 weeks
Where a drug is not listed here, its prescribing information sets out its own dose steps.
How soon it acts
- Wegovy — Noticeable effects within 4–8 weeks; maximum weight loss typically reached by 60–68 weeks
- Contrave — Appetite and craving changes typically within 4–8 weeks; significant weight loss by 16–24 weeks
Heart and metabolic findings
- Wegovy — The SELECT trial (n=17,604) demonstrated a 20% reduction in major adverse cardiovascular events (MACE — heart attack, stroke, or cardiovascular death) vs. placebo in adults with established cardiovascular disease and obesity, without diabetes.
- Contrave — The LIGHT cardiovascular outcomes trial was terminated early due to a protocol violation and did not provide a definitive answer on CV outcomes.
As stated in each drug’s trial record — not a claim about which drug protects the heart more.
Other findings recorded
- Wegovy — 20% reduction in heart attacks and strokes (SELECT trial, established CVD); improved blood pressure and cholesterol across STEP trials
- Contrave — May help specifically with emotional eating and food cravings; bupropion's antidepressant effect may be beneficial if low mood contributes to overeating
If you stop taking it
- Wegovy — In STEP 4, stopping semaglutide after a 20-week run-in led to significant weight regain.
- Contrave — Weight regain after stopping is expected.
Common questions
Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice
Clinical evidence — Semaglutide and Naltrexone / Bupropion ER
No head-to-head trial has compared these two drugs.
- STEP 1 — Semaglutide (injection): 1,961 adults with obesity or overweight with comorbidities, no type 2 diabetes, 68 weeks. New England Journal of Medicine, 2021. View source ↗
- COR-BMOD — Naltrexone / Bupropion: Adults with obesity, with intensive behaviour therapy, 56 weeks. Obesity, 2011. View source ↗
- COR-I — Naltrexone / Bupropion: 1,742 adults with obesity or overweight with comorbidities, 56 weeks. The Lancet, 2010. View source ↗
- Wegovy (semaglutide) injection and tablets — FDA prescribing information — DailyMed View source ↗
- Contrave (naltrexone and bupropion extended-release) — FDA prescribing information — DailyMed View source ↗
Next step most people take
Built with agentic AI tools and not a substitute for medical advice
Last reviewed: